STOCK TITAN

Bausch + Lomb Corporation - BLCO STOCK NEWS

Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.

Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.

Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.

Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.

Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.

With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.

Rhea-AI Summary
Bausch + Lomb discloses financial information regarding the proposed acquisition of XIIDRA and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
-
Rhea-AI Summary
Bausch + Lomb announces 13 podium and poster presentations at ESCRS annual meeting, featuring surgical technologies like SeeLuma™, MIMS®, and IC-8® Apthera IOL. Educational events and networking opportunities will also be held.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb CEO to participate in 2023 Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
Rhea-AI Summary
Bausch + Lomb announces expiration of HSR Act waiting period for acquisition of XIIDRA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags

FAQ

What is the current stock price of Bausch + Lomb Corporation (BLCO)?

The current stock price of Bausch + Lomb Corporation (BLCO) is $18 as of December 20, 2024.

What is the market cap of Bausch + Lomb Corporation (BLCO)?

The market cap of Bausch + Lomb Corporation (BLCO) is approximately 6.3B.

What does Bausch + Lomb Corporation do?

Bausch + Lomb Corporation operates in the vision care industry, offering products in vision care, surgical, and ophthalmic pharmaceuticals segments.

When did Bausch + Lomb become a public company?

Bausch + Lomb became a public company in 2022 after spinning off from Bausch Health.

What are the primary segments Bausch + Lomb operates in?

The primary segments are vision care, surgical, and ophthalmic pharmaceuticals.

What are some key products in Bausch + Lomb's vision care segment?

Key products include Biotrue and Lumify, along with various contact lenses.

What does Bausch + Lomb offer in its surgical segment?

The surgical segment includes intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments.

What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?

This segment features over 100 products, including Xipere, Vyzulta, and Lotemax, for treating various eye conditions.

Where is Bausch + Lomb Corporation headquartered?

The company is headquartered in Madrid, Spain.

What market share does Bausch + Lomb hold in the contact lenses market?

Bausch + Lomb controls 10% of the contact lenses market.

What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?

Its extensive lineup of over 100 eye care products helps Bausch + Lomb maintain a leadership position in the market.

What is Bausch + Lomb's commitment towards its products and services?

Bausch + Lomb is committed to innovation and quality, continuously enhancing its offerings through new projects and partnerships.

Bausch + Lomb Corporation

NYSE:BLCO

BLCO Rankings

BLCO Stock Data

6.34B
40.51M
88.47%
10.91%
0.27%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States of America
VAUGHAN